Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. | More News
Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.
Zach Gerhart Hines Jakob Bondo Hansen Novo Nordisk Obesity Research At Novo Nordisk Bioinnovation Institute Novo Nordisk Foundation Center
Source: pipelinereview.com